Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) – Research analysts at HC Wainwright raised their FY2024 earnings estimates for Tempest Therapeutics in a report released on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($1.27) per share for the year, up from their previous forecast of ($1.54). HC Wainwright has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($1.07) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.04) EPS.
TPST has been the topic of several other research reports. Piper Sandler dropped their price objective on shares of Tempest Therapeutics from $8.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday. William Blair reissued an “outperform” rating on shares of Tempest Therapeutics in a research note on Wednesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $20.00.
Tempest Therapeutics Price Performance
NASDAQ:TPST opened at $0.97 on Friday. Tempest Therapeutics has a one year low of $0.86 and a one year high of $6.00. The company’s 50-day simple moving average is $1.20 and its 200 day simple moving average is $1.96.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of TPST. Empower Advisory Group LLC purchased a new position in Tempest Therapeutics in the third quarter worth about $49,000. Dimensional Fund Advisors LP purchased a new position in Tempest Therapeutics in the second quarter worth about $55,000. Fullcircle Wealth LLC purchased a new position in Tempest Therapeutics in the third quarter worth about $87,000. Finally, Virtu Financial LLC raised its holdings in shares of Tempest Therapeutics by 69.2% during the first quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after purchasing an additional 11,689 shares during the last quarter. 22.52% of the stock is owned by hedge funds and other institutional investors.
Tempest Therapeutics Company Profile
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
See Also
- Five stocks we like better than Tempest Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- The How And Why of Investing in Oil Stocks
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Overbought Stocks Explained: Should You Trade Them?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
